| 1.135 0.095 (9.13%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 |
1-year : | 1.71 |
| Resists | First : | 1.25 |
Second : | 1.46 |
| Pivot price | 1.08 |
|||
| Supports | First : | 1.09 |
Second : | 0.99 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.09  |
| MA(100) : | 1 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.9 |
D(3) : | 28.9 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 1.54 | Low : | 0.49 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CNTX ] has closed below upper band by 14.9%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.16 - 1.17 | 1.17 - 1.17 |
| Low: | 1.03 - 1.03 | 1.03 - 1.04 |
| Close: | 1.13 - 1.13 | 1.13 - 1.14 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fri, 07 Nov 2025
Context Therapeutics Inc. Presents Data on CT-95 and CT-202 Bispecific Antibodies at SITC 2025 Annual Meeting - Quiver Quantitative
Fri, 07 Nov 2025
Context Therapeutics (NASDAQ: CNTX) Highlights CT-95 and CT-202 at SITC Meeting - Stock Titan
Thu, 06 Nov 2025
D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation - Nasdaq
Wed, 05 Nov 2025
Context Therapeutics (NASDAQ: CNTX) Q3: CTIM-76 shows RECIST response; no DLT observed - Stock Titan
Mon, 20 Oct 2025
Context Therapeutics Regains Nasdaq Compliance - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 75.3 (%) |
| Shares Short | 485 (K) |
| Shares Short P.Month | 848 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -4.73 |
| PEG Ratio | 0 |
| Price to Book value | 1.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|